DXR: SEC Form NT NPORT-P filed by Daxor Corporation
Stocks in this Quantisnow insightHealth Care
Historical context for DXR
Across the 12 sessions after earlier DXR headlines, the stock closed higher 5 times and lower 7 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | DXR | SPY |
|---|---|---|---|
| Apr 28, 2026 | Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis | +5.4% | -0.5% |
| Apr 8, 2026 | Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center | +2.3% | +2.5% |
| Mar 26, 2026 | Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 | -2.9% | -1.8% |
| Mar 17, 2026 | Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions | +0.2% | +0.3% |
| Mar 10, 2026 | Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress | +1.6% | -0.2% |
| Mar 9, 2026 | Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 | -0.7% | +0.9% |
Quantisnow market dataNASDAQ
DXR
Daxor Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
Get push alerts for DXR
Full DXR profile on Quantisnow Follow DXR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time